About Doug Kwon, MD, PhD

Dr. Douglas Kwon is a physician scientist and Director of Clinical Operations at the Ragon Institute of MGH, MIT and Harvard. He has a clinical practice in the division of Infectious Diseases at Massachusetts General Hospital. He received his M.D. Ph.D. degrees from New York University and then underwent Internal Medicine training at the University of California, San Francisco and New York Hospital/Weill Cornell Medical Center. He then completed his training in the combined Massachusetts General Hospital and Brigham and Women’s Hospital Infectious Disease fellowship program. 

The focus of his current research is understanding the role of mucosal tissues in HIV acquisition and disease progression. His lab is involved in developing and applying new technologies to overcome the technical barriers that have impeded our understanding of mucosal immunity to date. This includes the application of novel techniques and functional assays to assess HIV-specific immune responses and the microbiome at mucosal sites. 

See further details at www.kwonlab.org

 

Departments, Centers, & Programs:

Treats:

Locations

Infectious Disease Associates
55 Fruit Street
Boston, MA 02114-2696
617-726-3813

Medical Education

  • MD, PhD, New York University School of Medicine
  • Residency, New York Presbyterian Hospital Weill Cornell
  • Fellowship, Brigham and Women's Hospital

American Board Certifications

  • Internal Medicine, American Board of Internal Medicine
  • Infectious Disease, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Research

The focus of the Kwon lab is the application of new technologies to the study of immune responses against HIV at mucosal surfaces.

Mucosal surfaces represent both the primary site of HIV transmission and the largest reservoir of viral replication. Despite this, the immune response to HIV has largely been studied in the peripheral blood, which contains just 2-3% of all lymphocytes- a small minority relative to the 60-90% of the body's T and B cells that reside at mucosal sites. One of the greatest barriers to a more detailed understanding of these responses is the inherently small amount of material that can be obtained from mucosal sampling. We are therefore employing new technologies, such as high throughput sequencing and nanowell technologies, to simultaneously capture multiple measures of viral, metagenomic, and adaptive immune factors important for HIV immunity and pathogenesis.

Publications